Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16295780,elimination of half life,"In vitro, the elimination of half life was achieved at 2.88+/-1.14 h for NAC and at 3.68+/-1.84 h for total NAC.",Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16295780/),h,2.88,772,DB06151,Acetylcysteine
,16295780,elimination of half life,"In vitro, the elimination of half life was achieved at 2.88+/-1.14 h for NAC and at 3.68+/-1.84 h for total NAC.",Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16295780/),h,3.68,773,DB06151,Acetylcysteine
,16295780,body clearances,"The body clearances were 1.23+/-0.77 L h(-1) kg(-1) and 0.56+/-0.27 L h(-1) kg(-1) and the volumes of distribution were 3.07+/-0.10 L kg(-1) and 3.00+/-0.11 L kg(-1), respectively.",Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16295780/),[l] / [h·kg],1.23,774,DB06151,Acetylcysteine
,16295780,body clearances,"The body clearances were 1.23+/-0.77 L h(-1) kg(-1) and 0.56+/-0.27 L h(-1) kg(-1) and the volumes of distribution were 3.07+/-0.10 L kg(-1) and 3.00+/-0.11 L kg(-1), respectively.",Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16295780/),[l] / [h·kg],0.56,775,DB06151,Acetylcysteine
,16295780,volumes of distribution,"The body clearances were 1.23+/-0.77 L h(-1) kg(-1) and 0.56+/-0.27 L h(-1) kg(-1) and the volumes of distribution were 3.07+/-0.10 L kg(-1) and 3.00+/-0.11 L kg(-1), respectively.",Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16295780/),[l] / [kg],3.07,776,DB06151,Acetylcysteine
,16295780,volumes of distribution,"The body clearances were 1.23+/-0.77 L h(-1) kg(-1) and 0.56+/-0.27 L h(-1) kg(-1) and the volumes of distribution were 3.07+/-0.10 L kg(-1) and 3.00+/-0.11 L kg(-1), respectively.",Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16295780/),[l] / [kg],3.00,777,DB06151,Acetylcysteine
,9029053,Liver,"Liver concentrations of 4-ene VPA and alpha-fluoro-4-ene VPA were 0.96 +/- 0.11 and 0.89 +/- 0.19 micromol/g of wet liver, respectively, at 1 hr after the dose.",A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029053/),μ,0.96,9610,DB06151,Acetylcysteine
,9029053,Liver,"Liver concentrations of 4-ene VPA and alpha-fluoro-4-ene VPA were 0.96 +/- 0.11 and 0.89 +/- 0.19 micromol/g of wet liver, respectively, at 1 hr after the dose.",A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029053/),μ,0.89,9611,DB06151,Acetylcysteine
,3360052,volume of distribution (VSS),Reduced NAC had a volume of distribution (VSS) of 0.59 l.kg-1 and a plasma clearance of 0.84 l.h-1.kg-1.,Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360052/),[l] / [kg],0.59,15136,DB06151,Acetylcysteine
,3360052,plasma clearance,Reduced NAC had a volume of distribution (VSS) of 0.59 l.kg-1 and a plasma clearance of 0.84 l.h-1.kg-1.,Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360052/),[l] / [h·kg],0.84,15137,DB06151,Acetylcysteine
,3360052,terminal half-life,The terminal half-life after intravenous administration was 1.95 h.,Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360052/),h,1.95,15138,DB06151,Acetylcysteine
,3360052,oral bioavailability,The oral bioavailability was 4.0%.,Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360052/),%,4.0,15139,DB06151,Acetylcysteine
,3360052,volume of distribution (VSS),"Based on total NAC concentration, its volume of distribution (VSS) was 0.47 l.kg-1 and its plasma clearance was 0.11 l.h-1.kg-1.",Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360052/),[l] / [kg],0.47,15140,DB06151,Acetylcysteine
,3360052,plasma clearance,"Based on total NAC concentration, its volume of distribution (VSS) was 0.47 l.kg-1 and its plasma clearance was 0.11 l.h-1.kg-1.",Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360052/),[l] / [h·kg],0.11,15141,DB06151,Acetylcysteine
,3360052,terminal half-life,The terminal half-life was 5.58 h after intravenous administration and 6.25 h after oral administration.,Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360052/),h,5.58,15142,DB06151,Acetylcysteine
,3360052,terminal half-life,The terminal half-life was 5.58 h after intravenous administration and 6.25 h after oral administration.,Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360052/),h,6.25,15143,DB06151,Acetylcysteine
,3360052,Oral bioavailability,Oral bioavailability of total NAC was 9.1%.,Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360052/),%,9.1,15144,DB06151,Acetylcysteine
,10319153,total body clearance,DDTC has a low affinity to rat tissue and the total body clearance was 9.0 +/- 3.4 ml/min/kg.,"Metabolism and pharmacokinetics of S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319153/),[ml] / [kg·min],9.0,18418,DB06151,Acetylcysteine
,10319153,mean residence time (MRT),The mean residence time (MRT) was 111.5 +/- 16.3 min.,"Metabolism and pharmacokinetics of S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine in rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319153/),min,111.5,18419,DB06151,Acetylcysteine
,10319153,maximal plasma concentration (Cmax),"After oral administration of 20 mg/kg AC-DDTC, maximal plasma concentration (Cmax) was 3.8 +/- 0.2 nmol/ml and the bioavailability was 7.04%.","Metabolism and pharmacokinetics of S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319153/),[nM] / [ml],3.8,18420,DB06151,Acetylcysteine
,10319153,bioavailability,"After oral administration of 20 mg/kg AC-DDTC, maximal plasma concentration (Cmax) was 3.8 +/- 0.2 nmol/ml and the bioavailability was 7.04%.","Metabolism and pharmacokinetics of S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319153/),%,7.04,18421,DB06151,Acetylcysteine
,10319153,Cmax,Cmax for DDTC at a dose of 120 mg/kg AC-DDTC was 40.1 +/- 2.2 nmol/ml.,"Metabolism and pharmacokinetics of S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319153/),[nM] / [ml],40.1,18422,DB06151,Acetylcysteine
,10319153,MRT,MRT was 47.1 +/- 2.8 min at a dose of 20 mg/kg and 110.5 +/- 6.0 min at 120 mg/kg.,"Metabolism and pharmacokinetics of S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine in rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319153/),min,47.1,18423,DB06151,Acetylcysteine
,10319153,MRT,MRT was 47.1 +/- 2.8 min at a dose of 20 mg/kg and 110.5 +/- 6.0 min at 120 mg/kg.,"Metabolism and pharmacokinetics of S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine in rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319153/),min,110.5,18424,DB06151,Acetylcysteine
,31330211,zeta potential,The average size of spherical PTX-NHOA micelles was 162.7 nm with a zeta potential of -27.6 mv.,The enhancing effect of N-acetylcysteine modified hyaluronic acid-octadecylamine micelles on the oral absorption of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330211/),mv,-,22319,DB06151,Acetylcysteine
,31330211,zeta potential,The average size of spherical PTX-NHOA micelles was 162.7 nm with a zeta potential of -27.6 mv.,The enhancing effect of N-acetylcysteine modified hyaluronic acid-octadecylamine micelles on the oral absorption of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330211/),mv,27.6,22320,DB06151,Acetylcysteine
,31330211,encapsulation efficiency (EE),"The encapsulation efficiency (EE) and drug loading (DL) of PTX-NHOA micelles were 92.64% and 6.96%, respectively.",The enhancing effect of N-acetylcysteine modified hyaluronic acid-octadecylamine micelles on the oral absorption of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330211/),%,92.64,22321,DB06151,Acetylcysteine
,31330211,drug loading (DL),"The encapsulation efficiency (EE) and drug loading (DL) of PTX-NHOA micelles were 92.64% and 6.96%, respectively.",The enhancing effect of N-acetylcysteine modified hyaluronic acid-octadecylamine micelles on the oral absorption of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330211/),%,6.96,22322,DB06151,Acetylcysteine
,10638393,elimination half-life,"In study I, the mean elimination half-life of N-acetylcysteine was 11 h (range 7.8-15.2 h).",Pharmacokinetics of intravenous N-acetylcysteine in pre-term new-born infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638393/),h,11,23990,DB06151,Acetylcysteine
,10638393,plasma clearance,The mean plasma clearance of N-acetylcysteine was 37 ml/kg/h (range 13-62 ml/kg/h) and the mean volume of distribution was 573 ml/kg (range 167-1010 ml/kg).,Pharmacokinetics of intravenous N-acetylcysteine in pre-term new-born infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638393/),[ml] / [h·kg],37,23991,DB06151,Acetylcysteine
,10638393,volume of distribution,The mean plasma clearance of N-acetylcysteine was 37 ml/kg/h (range 13-62 ml/kg/h) and the mean volume of distribution was 573 ml/kg (range 167-1010 ml/kg).,Pharmacokinetics of intravenous N-acetylcysteine in pre-term new-born infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638393/),[ml] / [kg],573,23992,DB06151,Acetylcysteine
,3091779,peak ulcers,"These doses produced peak ulcers of 0.15 to 0.22 cm2, respectively, one to five days after injection.",Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2,0.15,26156,DB06151,Acetylcysteine
,3091779,peak ulcers,"These doses produced peak ulcers of 0.15 to 0.22 cm2, respectively, one to five days after injection.",Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2,0.22,26157,DB06151,Acetylcysteine
,3091779,area X time,The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,0.89,26158,DB06151,Acetylcysteine
,3091779,area X time,The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,3.11,26159,DB06151,Acetylcysteine
,3091779,area under the curve [AUC],The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,0.89,26160,DB06151,Acetylcysteine
,3091779,area under the curve [AUC],The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,3.11,26161,DB06151,Acetylcysteine
,3091779,AUC,DMSO significantly increased the AUC for MMC in skin from 0.89 to 2.25 ng/h/mL of tissue (P less than .05).,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),[ng] / [h·ml],0.89,26162,DB06151,Acetylcysteine
,3091779,AUC,DMSO significantly increased the AUC for MMC in skin from 0.89 to 2.25 ng/h/mL of tissue (P less than .05).,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),[ng] / [h·ml],2,26163,DB06151,Acetylcysteine
,8595092,minimum absorption,"Based on the excretion of radioactivity in urine, the minimum absorption was about 73%.","Fate and distribution of [14C]S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine, an antimutagenic mixed disulfide from disulfiram, in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595092/),%,73,27870,DB06151,Acetylcysteine
,8595092,Cmax,"Mean Cmax value for N,N-diethyldithiocarbamate (DDTC) after oral dose of AC-DDTC (20 mg/kg) was 3.8 +/- 0.2 nmol/ml at 15 min and the mean residence time was 47.1 +/- 2.8 min.","Fate and distribution of [14C]S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine, an antimutagenic mixed disulfide from disulfiram, in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595092/),[nM] / [ml],3.8,27871,DB06151,Acetylcysteine
,8595092,mean residence time,"Mean Cmax value for N,N-diethyldithiocarbamate (DDTC) after oral dose of AC-DDTC (20 mg/kg) was 3.8 +/- 0.2 nmol/ml at 15 min and the mean residence time was 47.1 +/- 2.8 min.","Fate and distribution of [14C]S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine, an antimutagenic mixed disulfide from disulfiram, in rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595092/),min,47.1,27872,DB06151,Acetylcysteine
,12189531,100%,"Myeloid progenitors were more sensitive than erythroid progenitors, expressed as 100% inhibition of colony formation (68.7 +/- 7.5 microg.h/ml and 140.3 +/- 35.7, respectively).",The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189531/),[h·μg] / [ml],68.7,30874,DB06151,Acetylcysteine
,12189531,100%,"Myeloid progenitors were more sensitive than erythroid progenitors, expressed as 100% inhibition of colony formation (68.7 +/- 7.5 microg.h/ml and 140.3 +/- 35.7, respectively).",The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189531/),,140,30875,DB06151,Acetylcysteine
,34275158,CL,"Estimates for CL, central (V1), and peripheral volume (V2), and intercompartment clearance were 14.7 L/h, 23.2 L, 17.1 L, 3.99 L/h, respectively, for a 70-kg person.",Population Pharmacokinetic Analysis of N-Acetylcysteine in Pediatric Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275158/),[l] / [h],14.7,31864,DB06151,Acetylcysteine
,34275158,central (V1),"Estimates for CL, central (V1), and peripheral volume (V2), and intercompartment clearance were 14.7 L/h, 23.2 L, 17.1 L, 3.99 L/h, respectively, for a 70-kg person.",Population Pharmacokinetic Analysis of N-Acetylcysteine in Pediatric Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplant. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275158/),l,23.2,31865,DB06151,Acetylcysteine
,34275158,central (V1),"Estimates for CL, central (V1), and peripheral volume (V2), and intercompartment clearance were 14.7 L/h, 23.2 L, 17.1 L, 3.99 L/h, respectively, for a 70-kg person.",Population Pharmacokinetic Analysis of N-Acetylcysteine in Pediatric Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplant. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275158/),l,17.1,31866,DB06151,Acetylcysteine
,34275158,peripheral volume (V2),"Estimates for CL, central (V1), and peripheral volume (V2), and intercompartment clearance were 14.7 L/h, 23.2 L, 17.1 L, 3.99 L/h, respectively, for a 70-kg person.",Population Pharmacokinetic Analysis of N-Acetylcysteine in Pediatric Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplant. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275158/),l,23.2,31867,DB06151,Acetylcysteine
,34275158,peripheral volume (V2),"Estimates for CL, central (V1), and peripheral volume (V2), and intercompartment clearance were 14.7 L/h, 23.2 L, 17.1 L, 3.99 L/h, respectively, for a 70-kg person.",Population Pharmacokinetic Analysis of N-Acetylcysteine in Pediatric Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplant. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275158/),l,17.1,31868,DB06151,Acetylcysteine
,34275158,intercompartment clearance,"Estimates for CL, central (V1), and peripheral volume (V2), and intercompartment clearance were 14.7 L/h, 23.2 L, 17.1 L, 3.99 L/h, respectively, for a 70-kg person.",Population Pharmacokinetic Analysis of N-Acetylcysteine in Pediatric Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplant. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275158/),[l] / [h],3.99,31869,DB06151,Acetylcysteine
,34275158,Residual,Residual variability was estimated to be 16%.,Population Pharmacokinetic Analysis of N-Acetylcysteine in Pediatric Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275158/),%,16,31870,DB06151,Acetylcysteine
,19701261,pulse,"Her pulse was 70 bpm, BP 149/63 mmHg with an unremarkable physical examination.",Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701261/),bpm,70,32876,DB06151,Acetylcysteine
,19701261,concentration,"Two-hour paracetamol concentration was 2628 micromol/L falling to 2216 micromol/L, 4 hours post-ingestion.",Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701261/),,262,32877,DB06151,Acetylcysteine
,19701261,concentration,"Two-hour paracetamol concentration was 2628 micromol/L falling to 2216 micromol/L, 4 hours post-ingestion.",Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701261/),,2216,32878,DB06151,Acetylcysteine
,26052837,elimination phase half-life,The elimination phase half-life of NAC was approximately 34 min.,Intravenous Administration of Stable-Labeled N-Acetylcysteine Demonstrates an Indirect Mechanism for Boosting Glutathione and Improving Redox Status. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26052837/),min,34,32999,DB06151,Acetylcysteine
,2029805,peak plasma concentration,After an oral dose of N-acetylcysteine 200 to 400 mg the peak plasma concentration of 0.35 to 4 mg/L is achieved within 1 to 2 hours.,Clinical pharmacokinetics of N-acetylcysteine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),[mg] / [l],0.35 to 4,33002,DB06151,Acetylcysteine
,2029805,volume of distribution,"The volume of distribution ranges from 0.33 to 0.47 L/kg and protein binding is significant, reaching approximately 50% 4 hours after the dose.",Clinical pharmacokinetics of N-acetylcysteine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),[l] / [kg],0.33 to 0.47,33003,DB06151,Acetylcysteine
,2029805,Renal clearance,Renal clearance has been reported as 0.190 to 0.211 L/h/kg and approximately 70% of the total body clearance is nonrenal.,Clinical pharmacokinetics of N-acetylcysteine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),[l] / [h·kg],0.190 to 0.211,33004,DB06151,Acetylcysteine
,2029805,terminal half-life,"Following oral administration, reduced N-acetylcysteine has a terminal half-life of 6.25h.",Clinical pharmacokinetics of N-acetylcysteine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),h,6.25,33005,DB06151,Acetylcysteine
,27668024,Cmax,"The concentration-versus-time profiles were similar for the 2 formulations, with mean Cmax of 26.5 μg/mL for effervescent NAC tablets and 28.4 μg/mL for oral solution NAC.","Effervescent N-Acetylcysteine Tablets versus Oral Solution N-Acetylcysteine in Fasting Healthy Adults: An Open-Label, Randomized, Single-Dose, Crossover, Relative Bioavailability Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668024/),[μg] / [ml],26.5,33651,DB06151,Acetylcysteine
,27668024,Cmax,"The concentration-versus-time profiles were similar for the 2 formulations, with mean Cmax of 26.5 μg/mL for effervescent NAC tablets and 28.4 μg/mL for oral solution NAC.","Effervescent N-Acetylcysteine Tablets versus Oral Solution N-Acetylcysteine in Fasting Healthy Adults: An Open-Label, Randomized, Single-Dose, Crossover, Relative Bioavailability Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668024/),[μg] / [ml],28.4,33652,DB06151,Acetylcysteine
,27350323,zeta potential,"After coating, changed particle size from 50.76 ± 2.21 nm to 88.64 ± 1.25 nm and reversed zeta potential from -20.38 ± 0.39 mV to 22.51 ± 0.34 mV was observed.",Potential advantages of a novel chitosan-N-acetylcysteine surface modified nanostructured lipid carrier on the performance of ophthalmic delivery of curcumin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27350323/),mv,-,35341,DB06151,Acetylcysteine
,27350323,zeta potential,"After coating, changed particle size from 50.76 ± 2.21 nm to 88.64 ± 1.25 nm and reversed zeta potential from -20.38 ± 0.39 mV to 22.51 ± 0.34 mV was observed.",Potential advantages of a novel chitosan-N-acetylcysteine surface modified nanostructured lipid carrier on the performance of ophthalmic delivery of curcumin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27350323/),mv,20.38,35342,DB06151,Acetylcysteine
,27350323,zeta potential,"After coating, changed particle size from 50.76 ± 2.21 nm to 88.64 ± 1.25 nm and reversed zeta potential from -20.38 ± 0.39 mV to 22.51 ± 0.34 mV was observed.",Potential advantages of a novel chitosan-N-acetylcysteine surface modified nanostructured lipid carrier on the performance of ophthalmic delivery of curcumin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27350323/),mv,22.51,35343,DB06151,Acetylcysteine
,14752063,serum clearance half-life,N-acetylcysteine serum clearance half-life was 9 to 11 min.,Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14752063/),min,9 to 11,36319,DB06151,Acetylcysteine
,14752063,tumor volume,Enhanced chemotherapy reduced intracerebral tumor volume to 4.3 +/- 1.0 mm(3) compared with 29.1 +/- 4.1 mm(3) in untreated animals (P < 0.0001).,Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14752063/),mm(3),4.3,36320,DB06151,Acetylcysteine
,14752063,tumor volume,Enhanced chemotherapy reduced intracerebral tumor volume to 4.3 +/- 1.0 mm(3) compared with 29.1 +/- 4.1 mm(3) in untreated animals (P < 0.0001).,Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14752063/),mm(3,29.1,36321,DB06151,Acetylcysteine
,14752063,Tumor volume,Tumor volume was 3.7 +/- 0.6 mm(3) in rats that received N-acetylcysteine before and sodium thiosulfate after chemotherapy.,Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14752063/),mm(3),3.7,36322,DB06151,Acetylcysteine
,9653946,Recovery rates,"Recovery rates of cysteine and N-acetylcysteine added to human plasma were 94.6 and 99.6%, respectively.",Analysis of cysteine and N-acetylcysteine in human plasma by high-performance liquid chromatography at the basal state and after oral administration of N-acetylcysteine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653946/),%,94.6,36908,DB06151,Acetylcysteine
,9653946,Recovery rates,"Recovery rates of cysteine and N-acetylcysteine added to human plasma were 94.6 and 99.6%, respectively.",Analysis of cysteine and N-acetylcysteine in human plasma by high-performance liquid chromatography at the basal state and after oral administration of N-acetylcysteine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653946/),%,99.6,36909,DB06151,Acetylcysteine
,3829578,time of peak excretion rate,"The mean time of peak excretion rate was 1.3 to 3.7 hours for acetaminophen, its glucuronide, sulfate, cysteine, mercapturate, and methoxy metabolites but 13.5 hours for methylthioacetaminophen.",Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829578/),h,1.3 to 3.7,37952,DB06151,Acetylcysteine
,3829578,time of peak excretion rate,"The mean time of peak excretion rate was 1.3 to 3.7 hours for acetaminophen, its glucuronide, sulfate, cysteine, mercapturate, and methoxy metabolites but 13.5 hours for methylthioacetaminophen.",Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829578/),h,13.5,37953,DB06151,Acetylcysteine
,3829578,half-life,The mean half-life of acetaminophen was 3.1 hours and the mean half-life of the metabolites other than methylthioacetaminophen ranged from 4.1 to 5.7 hours.,Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829578/),h,3.1,37954,DB06151,Acetylcysteine
,3829578,half-life,The mean half-life of acetaminophen was 3.1 hours and the mean half-life of the metabolites other than methylthioacetaminophen ranged from 4.1 to 5.7 hours.,Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829578/),h,4.1 to 5.7,37955,DB06151,Acetylcysteine
,15619135,Whole-body clearance (CL),Whole-body clearance (CL) was 0.58 l kg(-1) h(-1) (95% CI 0.44-0.72) for reduced NAC (NACR) and 0.16 (0.13-0.20) l kg(-1) h(-1) for total NAC (NACT).,Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619135/),[l] / [h·kg],0.58,46050,DB06151,Acetylcysteine
,15619135,Whole-body clearance (CL),Whole-body clearance (CL) was 0.58 l kg(-1) h(-1) (95% CI 0.44-0.72) for reduced NAC (NACR) and 0.16 (0.13-0.20) l kg(-1) h(-1) for total NAC (NACT).,Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619135/),[l] / [h·kg],0.16,46051,DB06151,Acetylcysteine
,15619135,central volume of distribution (V1),The central volume of distribution (V1) was 0.064 (0.008-0.12) l kg(-1) for NACR and 0.037 (0.02-0.06) l kg(-1) for NACT.,Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619135/),[l] / [kg],0.064,46052,DB06151,Acetylcysteine
,15619135,central volume of distribution (V1),The central volume of distribution (V1) was 0.064 (0.008-0.12) l kg(-1) for NACR and 0.037 (0.02-0.06) l kg(-1) for NACT.,Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619135/),[l] / [kg],0.037,46053,DB06151,Acetylcysteine
,15657783,steady state,"Baseline NAC was on average 454 ng ml(-1); its concentration increased to 9,253 ng ml(-1) at the second infusion and attained a steady state between 14,000 ng ml(-1) and 17,000 ng ml(-1) at the fourth dose.",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[ng] / [ml],"14,000",48595,DB06151,Acetylcysteine
,15657783,steady state,"Baseline NAC was on average 454 ng ml(-1); its concentration increased to 9,253 ng ml(-1) at the second infusion and attained a steady state between 14,000 ng ml(-1) and 17,000 ng ml(-1) at the fourth dose.",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[ng] / [ml],"17,000",48596,DB06151,Acetylcysteine
,15657783,C (max),"We observed a C (max) of 53,458 ng ml(-1) with a t (max) of 3.0 h.",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[ng] / [ml],"53,458",48597,DB06151,Acetylcysteine
,15657783,t (max),"We observed a C (max) of 53,458 ng ml(-1) with a t (max) of 3.0 h.",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),h,3.0,48598,DB06151,Acetylcysteine
,15657783,Plasma clearance,Plasma clearance was 1.25 l h(-1) and dialytic clearance 5.52 l h(-1).,Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[l] / [h],1.25,48599,DB06151,Acetylcysteine
,15657783,dialytic clearance,Plasma clearance was 1.25 l h(-1) and dialytic clearance 5.52 l h(-1).,Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[l] / [h],5.52,48600,DB06151,Acetylcysteine
,15657783,total body clearance,"The dialytic clearance is effective, the total body clearance being reduced to 1.25 l h(-1).",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[l] / [h],1.25,48601,DB06151,Acetylcysteine
,10736124,AUC,Mean AUC for the control group (77.1+/-5.7 g x min/dL) was significantly lower than the mean AUC for the treatment group (84.5+/-4.7 g x min/dL); P =.01).,Failure of intravenous N-acetylcysteine to reduce methemoglobin produced by sodium nitrite in human volunteers: A randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736124/),[g·min] / [dl],77.1,52121,DB06151,Acetylcysteine
,10736124,AUC,Mean AUC for the control group (77.1+/-5.7 g x min/dL) was significantly lower than the mean AUC for the treatment group (84.5+/-4.7 g x min/dL); P =.01).,Failure of intravenous N-acetylcysteine to reduce methemoglobin produced by sodium nitrite in human volunteers: A randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736124/),[g·min] / [dl],84.5,52122,DB06151,Acetylcysteine
,7039926,systemic bioavailability,"Following oral administration it is rapidly absorbed from the gastrointestinal tract, its systemic bioavailability being dose-dependent and ranging from 70 to 90%.",Clinical pharmacokinetics of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),%,70 to 90,56310,DB06151,Acetylcysteine
,7039926,volume of distribution,It distributes rapidly and evenly throughout most tissues and fluids and has a volume of distribution of approximately 0.9L/kg.,Clinical pharmacokinetics of paracetamol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[l] / [kg],0.9,56311,DB06151,Acetylcysteine
,7039926,plasma half-life,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),h,1.9 to 2.5,56312,DB06151,Acetylcysteine
,7039926,total body clearance,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[ml] / [kg·min],4.5 to 5.5,56313,DB06151,Acetylcysteine
,2750198,elimination t 1/2,"3. Exposure of rats to 78, 155, or 404 ppm DCP gave an elimination t 1/2 of 17 h, independent of exposure concentration.","Pharmacokinetics of S-[3-chloroprop-2-enyl]glutathione in rats following acute inhalation exposure to 1,3-dichloropropene. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2750198/),h,17,56575,DB06151,Acetylcysteine
,18923390,k(e),"The mean (+/-SD)k(e) and half-life were 0.486 +/- 0.084 days(-1) and 1.47+/- 0.30 days, respectively, and the C(max) was 1.2 (+/-2.92) nmol/ml serum.",Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923390/),1/[days],0.486,57729,DB06151,Acetylcysteine
,18923390,half-life,"The mean (+/-SD)k(e) and half-life were 0.486 +/- 0.084 days(-1) and 1.47+/- 0.30 days, respectively, and the C(max) was 1.2 (+/-2.92) nmol/ml serum.",Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923390/),d,1.47,57730,DB06151,Acetylcysteine
,18923390,C(max),"The mean (+/-SD)k(e) and half-life were 0.486 +/- 0.084 days(-1) and 1.47+/- 0.30 days, respectively, and the C(max) was 1.2 (+/-2.92) nmol/ml serum.",Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923390/),[nM] / [ml·serum],1.2,57731,DB06151,Acetylcysteine
,19439490,elimination rate constant,"The mean elimination rate constant and elimination half-life were 0.42 +/- 0.09 days(-1) and 1.72 +/- 0.34 days, respectively, and estimates from the population model were in strong agreement with these data.",Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19439490/),1/[days],0.42,57790,DB06151,Acetylcysteine
,19439490,elimination half-life,"The mean elimination rate constant and elimination half-life were 0.42 +/- 0.09 days(-1) and 1.72 +/- 0.34 days, respectively, and estimates from the population model were in strong agreement with these data.",Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19439490/),d,1.72,57791,DB06151,Acetylcysteine
,31740394,bioavailability,"The method was utilized in pharmacokinetic study which showed that the bioavailability of NACA is significantly higher than NAC (67% and 15%, respectively).",Pharmacokinetic profile of N-acetylcysteine amide and its main metabolite in mice using new analytical method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31740394/),%,67,57864,DB06151,Acetylcysteine
,31740394,bioavailability,"The method was utilized in pharmacokinetic study which showed that the bioavailability of NACA is significantly higher than NAC (67% and 15%, respectively).",Pharmacokinetic profile of N-acetylcysteine amide and its main metabolite in mice using new analytical method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31740394/),%,15,57865,DB06151,Acetylcysteine
,9305490,area under the serum concentration-time curve,The area under the serum concentration-time curve was increased (152.34 mg/L.h +/- 50.38 s.d.) in cirrhotics compared with normal controls (93.86 mg/L.h +/- 9.60 s.d.) (P < 0.05).,Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9305490/),[mg] / [h·l],152.34,66589,DB06151,Acetylcysteine
,9305490,area under the serum concentration-time curve,The area under the serum concentration-time curve was increased (152.34 mg/L.h +/- 50.38 s.d.) in cirrhotics compared with normal controls (93.86 mg/L.h +/- 9.60 s.d.) (P < 0.05).,Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9305490/),[mg] / [h·l],93.86,66590,DB06151,Acetylcysteine
,9305490,clearance,The clearance of NAC was reduced in patients with chronic liver disease (4.52 L/h +/- 1.87 s.d.) compared with controls (6.47 L/h +/- 0.78: P < 0.01).,Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9305490/),[l] / [h],4.52,66591,DB06151,Acetylcysteine
,9305490,clearance,The clearance of NAC was reduced in patients with chronic liver disease (4.52 L/h +/- 1.87 s.d.) compared with controls (6.47 L/h +/- 0.78: P < 0.01).,Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9305490/),[l] / [h],6.47,66592,DB06151,Acetylcysteine
,30856016,elimination half-life,Initial paracetamol elimination half-life was 14.5 h.,A case of accidental neonatal paracetamol overdose with prolonged half-life and measured metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30856016/),h,14.5,75216,DB06151,Acetylcysteine
,18628444,peak acetaminophen concentration,Pharmacokinetic analysis revealed significantly prolonged acetaminophen absorption and a second peak acetaminophen concentration of 228 microg/mL approximately 48 hours postingestion.,Acetaminophen overdose with altered acetaminophen pharmacokinetics and hepatotoxicity associated with premature cessation of intravenous N-acetylcysteine therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18628444/),[μg] / [ml],228,86359,DB06151,Acetylcysteine
,7154136,half-life,Her serum acetaminophen concentration at 22 h was 485 micrograms/mL and declined with an unusually long half-life of 14 h.,Massive intoxication with acetaminophen and propoxyphene: unexpected survival and unusual pharmacokinetics of acetaminophen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7154136/),h,14,87767,DB06151,Acetylcysteine
,12069163,kon,"The kon, koff, and the elimination rate constant of protein-unbound drug (ke) were 0.23, 0.57, and 4.3 hr(-1).",In vivo kinetic analysis of covalent binding between N-acetyl-L-cysteine and plasma protein through the formation of mixed disulfide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12069163/),1/[hr],0.23,99703,DB06151,Acetylcysteine
,12069163,koff,"The kon, koff, and the elimination rate constant of protein-unbound drug (ke) were 0.23, 0.57, and 4.3 hr(-1).",In vivo kinetic analysis of covalent binding between N-acetyl-L-cysteine and plasma protein through the formation of mixed disulfide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12069163/),1/[hr],0.57,99704,DB06151,Acetylcysteine
,12069163,elimination rate constant of protein-unbound drug (ke),"The kon, koff, and the elimination rate constant of protein-unbound drug (ke) were 0.23, 0.57, and 4.3 hr(-1).",In vivo kinetic analysis of covalent binding between N-acetyl-L-cysteine and plasma protein through the formation of mixed disulfide in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12069163/),1/[hr],4.3,99705,DB06151,Acetylcysteine
,11864100,peak serum level,The mean peak serum level of cefetamet pivoxil in the placebo group was 4.86plus minus1.35 mg/L.,Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N-acetylcysteine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11864100/),[mg] / [l],4.86,100752,DB06151,Acetylcysteine
,11864100,elimination half-life,The elimination half-life was 3.56plus minus0.92 h.,Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N-acetylcysteine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11864100/),p,3.56,100753,DB06151,Acetylcysteine
,11864100,Cmax,The Cmax values differed significantly (p<0.05) only between the cisapride group (5.76plus minus1.50 mg/L) and the N-acetylcysteine group (4.53plus minus1.18 mg/L).,Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N-acetylcysteine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11864100/),plus,5.76,100754,DB06151,Acetylcysteine
,11864100,Cmax,The Cmax values differed significantly (p<0.05) only between the cisapride group (5.76plus minus1.50 mg/L) and the N-acetylcysteine group (4.53plus minus1.18 mg/L).,Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N-acetylcysteine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11864100/),plus,4.53,100755,DB06151,Acetylcysteine
,9209234,elimination half-life,"The acetaminophen elimination half-life was 3.1 +/- .8 hours (mean +/- SD; range, 1.3 to 4.0 hours; n = 12).",Tylenol Extended Relief overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209234/),h,3.1,104669,DB06151,Acetylcysteine
,4018078,plasma clearance,"However, its plasma clearance was significantly higher in NAR (45.7 ml kg-1 min-1) than in normal rats (25.2 ml kg-1 min-1).",Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),[ml] / [kg·min],45.7,106839,DB06151,Acetylcysteine
,4018078,plasma clearance,"However, its plasma clearance was significantly higher in NAR (45.7 ml kg-1 min-1) than in normal rats (25.2 ml kg-1 min-1).",Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),[ml] / [kg·min],25.2,106840,DB06151,Acetylcysteine
,4018078,association constant,The mercapturic acid bound to plasma albumin with an association constant of 2.24 X 10(5) M-1 and the number of binding sites was 1.18/mol albumin.,Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),1/[M],2.24 X 10(5),106841,DB06151,Acetylcysteine
,4018078,number of binding sites,The mercapturic acid bound to plasma albumin with an association constant of 2.24 X 10(5) M-1 and the number of binding sites was 1.18/mol albumin.,Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),1/[mol],1.18,106842,DB06151,Acetylcysteine
,4018078,plasma clearance,Concomitant administration of this mercapturic acid with equimolar amounts of albumin resulted in a marked decrease in the plasma clearance (26.2 ml kg-1 min-1) and an increase in the urinary secretion of this ligand in NAR.,Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),[ml] / [kg·min],26.2,106843,DB06151,Acetylcysteine
less,6799188,chemical plasma half-life,The chemical plasma half-life of the drug was less than 5 min.,"Disposition and metabolism in 1-(2-chloroethyl)-3-(2',3',4'-tri-o-acetyl, ribopyranosyl)-1-nitrosourea in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6799188/),min,5,111881,DB06151,Acetylcysteine
,2598989,maximum plasma concentration,The mean maximum plasma concentration after the initial loading dose was 554 mg/l.,The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),[mg] / [l],554,114983,DB06151,Acetylcysteine
,2598989,steady-state level,Concentrations then fell rapidly and after 12 h a mean steady-state level of about 35 mg/l was maintained.,The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),[mg] / [l],35,114984,DB06151,Acetylcysteine
,2598989,half-life,When the infusion was discontinued N-acetylcysteine disappeared with a half-life of 5.7 h.,The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),h,5.7,114985,DB06151,Acetylcysteine
,2598989,steady-state volume of distribution,"The mean steady-state volume of distribution, AUC, mean residence time and total clearance were 536 ml/kg, 1748 mg.h.l-1, 2.91 h and 3.18 ml.min-1.kg-1.",The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),[ml] / [kg],536,114986,DB06151,Acetylcysteine
,2598989,AUC,"The mean steady-state volume of distribution, AUC, mean residence time and total clearance were 536 ml/kg, 1748 mg.h.l-1, 2.91 h and 3.18 ml.min-1.kg-1.",The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),[h·mg] / [l],1748,114987,DB06151,Acetylcysteine
,2598989,AUC,"The mean steady-state volume of distribution, AUC, mean residence time and total clearance were 536 ml/kg, 1748 mg.h.l-1, 2.91 h and 3.18 ml.min-1.kg-1.",The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),h,2.91,114988,DB06151,Acetylcysteine
,2598989,mean residence time,"The mean steady-state volume of distribution, AUC, mean residence time and total clearance were 536 ml/kg, 1748 mg.h.l-1, 2.91 h and 3.18 ml.min-1.kg-1.",The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),[h·mg] / [l],1748,114989,DB06151,Acetylcysteine
,2598989,mean residence time,"The mean steady-state volume of distribution, AUC, mean residence time and total clearance were 536 ml/kg, 1748 mg.h.l-1, 2.91 h and 3.18 ml.min-1.kg-1.",The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),h,2.91,114990,DB06151,Acetylcysteine
,2598989,total clearance,"The mean steady-state volume of distribution, AUC, mean residence time and total clearance were 536 ml/kg, 1748 mg.h.l-1, 2.91 h and 3.18 ml.min-1.kg-1.",The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),[ml] / [kg·min],3.18,114991,DB06151,Acetylcysteine
less,2597179,Systemic plasma levels,Systemic plasma levels were less than 3 microM of the L-form and congruent to 40 microM of the D-form.,Metabolism of N-acetyl-L-cysteine. Some structural requirements for the deacetylation and consequences for the oral bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2597179/),μM,3,117363,DB06151,Acetylcysteine
,2597179,Systemic plasma levels,Systemic plasma levels were less than 3 microM of the L-form and congruent to 40 microM of the D-form.,Metabolism of N-acetyl-L-cysteine. Some structural requirements for the deacetylation and consequences for the oral bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2597179/),μM,40,117364,DB06151,Acetylcysteine
<,10859433,log count,All drugs showed a log count of <2.0 at 24 h with respect to the control while at 48 h all groups demonstrated a log count of <2.0.,"Comparative effect of thiamphenicol glycinate, thiamphenicol glycinate N-acetylcysteinate, amoxicillin plus clavulanic acid, ceftriaxone and clarithromycin on pulmonary clearance of Haemophilus influenzae in an animal model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859433/),,2.0,118307,DB06151,Acetylcysteine
,30243219,zeta potential,The average size of spherical NAC-HA-PTX micelles was 187 nm with a zeta potential of -25.38 mV.,N-acetylcysteine modified hyaluronic acid-paclitaxel conjugate for efficient oral chemotherapy through mucosal bioadhesion ability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243219/),m,25.38,119609,DB06151,Acetylcysteine
,33146843,accumulation ratio,The accumulation ratio was relatively consistent in both Chinese (mean ± standard deviation 1.5 ± 0.4) and Caucasian (1.4 ± 0.2) participants.,"Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146843/),,1.5,122991,DB06151,Acetylcysteine
,33146843,accumulation ratio,The accumulation ratio was relatively consistent in both Chinese (mean ± standard deviation 1.5 ± 0.4) and Caucasian (1.4 ± 0.2) participants.,"Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146843/),,1.4,122992,DB06151,Acetylcysteine
,33146843,half-life,"The half-life was 15.4 h in Chinese and 18.7 h in Caucasian participants, and the fraction of NAC excreted in urine in the 36 h following administration was 3.7% in Chinese and 3.8% in Caucasian participants.","Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146843/),h,15.4,122993,DB06151,Acetylcysteine
,33146843,half-life,"The half-life was 15.4 h in Chinese and 18.7 h in Caucasian participants, and the fraction of NAC excreted in urine in the 36 h following administration was 3.7% in Chinese and 3.8% in Caucasian participants.","Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146843/),h,18.7,122994,DB06151,Acetylcysteine
,33146843,fraction,"The half-life was 15.4 h in Chinese and 18.7 h in Caucasian participants, and the fraction of NAC excreted in urine in the 36 h following administration was 3.7% in Chinese and 3.8% in Caucasian participants.","Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146843/),%,3.7,122995,DB06151,Acetylcysteine
,33146843,fraction,"The half-life was 15.4 h in Chinese and 18.7 h in Caucasian participants, and the fraction of NAC excreted in urine in the 36 h following administration was 3.7% in Chinese and 3.8% in Caucasian participants.","Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146843/),%,3.8,122996,DB06151,Acetylcysteine
,27209292,CLformation,"At the mean weight (2.3 kg) and postnatal age (7.5 days), CLformation estimates (bootstrap 95% confidence interval; between-subject variability) were 0.049 L/h (0.038-0.062; 62 %) for glucuronidation, 0.21 L/h (0.17-0.24; 33 %) for sulfation, and 0.058 L/h (0.044-0.078; 72 %) for oxidation.","Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209292/),[l] / [h],0.049,128081,DB06151,Acetylcysteine
,27209292,CLformation,"At the mean weight (2.3 kg) and postnatal age (7.5 days), CLformation estimates (bootstrap 95% confidence interval; between-subject variability) were 0.049 L/h (0.038-0.062; 62 %) for glucuronidation, 0.21 L/h (0.17-0.24; 33 %) for sulfation, and 0.058 L/h (0.044-0.078; 72 %) for oxidation.","Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209292/),[l] / [h],0.21,128082,DB06151,Acetylcysteine
,27209292,CLformation,"At the mean weight (2.3 kg) and postnatal age (7.5 days), CLformation estimates (bootstrap 95% confidence interval; between-subject variability) were 0.049 L/h (0.038-0.062; 62 %) for glucuronidation, 0.21 L/h (0.17-0.24; 33 %) for sulfation, and 0.058 L/h (0.044-0.078; 72 %) for oxidation.","Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209292/),[l] / [h],0.058,128083,DB06151,Acetylcysteine
,25316328,maximum effect,"The population mean estimate of the concentration that induced a response halfway between the baseline and maximal pharmacological effect of paracetamol was 1302 μmol/L (242), the maximum effect of paracetamol was 0.534 (202; from baseline) and the maximum effect of NAC was 0.325 (9.03; from baseline).",Population pharmacokinetic-pharmacodynamic modelling to describe the effects of paracetamol and N-acetylcysteine on the international normalized ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25316328/),,0.534,136089,DB06151,Acetylcysteine
,25316328,maximum effect,"The population mean estimate of the concentration that induced a response halfway between the baseline and maximal pharmacological effect of paracetamol was 1302 μmol/L (242), the maximum effect of paracetamol was 0.534 (202; from baseline) and the maximum effect of NAC was 0.325 (9.03; from baseline).",Population pharmacokinetic-pharmacodynamic modelling to describe the effects of paracetamol and N-acetylcysteine on the international normalized ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25316328/),,0.325,136090,DB06151,Acetylcysteine
,3803419,Renal clearance,"Renal clearance constituted around 30% of total body clearance, which was 0.21 l/h/kg.",Pharmacokinetics of N-acetylcysteine in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803419/),[l] / [h·kg],0.21,137006,DB06151,Acetylcysteine
,3803419,total body clearance,"Renal clearance constituted around 30% of total body clearance, which was 0.21 l/h/kg.",Pharmacokinetics of N-acetylcysteine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803419/),[l] / [h·kg],0.21,137007,DB06151,Acetylcysteine
,3803419,Volume of distribution,"Volume of distribution was 0.33 l/kg, consistent with distribution mainly to extracellular water.",Pharmacokinetics of N-acetylcysteine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803419/),[l] / [kg],0.33,137008,DB06151,Acetylcysteine
,3803419,late elimination half-life,The late elimination half-life was 2.27 h and the mean residence time 1.62 h.,Pharmacokinetics of N-acetylcysteine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803419/),h,2.27,137009,DB06151,Acetylcysteine
,3803419,mean residence time,The late elimination half-life was 2.27 h and the mean residence time 1.62 h.,Pharmacokinetics of N-acetylcysteine in man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803419/),h,1.62,137010,DB06151,Acetylcysteine
,3803419,oral availability,"The oral availability of N-acetylcysteine varied between 6 and 10%, with the slow-release tablet having the lowest and the fast dissolving tablet the highest availability.",Pharmacokinetics of N-acetylcysteine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803419/),%,6 and 10,137011,DB06151,Acetylcysteine
,2395807,relative bioavailability,"A lysophospholipid, lysophosphatidylcholine, gave the highest peak concentration, with an increase in peak height of 450% and a relative bioavailability of 25.8%.",Nasal absorption enhancers for biosynthetic human growth hormone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395807/),%,25.8,144697,DB06151,Acetylcysteine
,2395807,relative bioavailability,"However, the greatest increase in AUC (291%) was achieved with the aminopeptidase inhibitor, amastatin, which gave a relative bioavailability of 28.9%.",Nasal absorption enhancers for biosynthetic human growth hormone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395807/),%,28.9,144698,DB06151,Acetylcysteine
,2395807,relative bioavailabilities,"A mucolytic agent, N-acetyl-L-cysteine, and a transmembrane fatty acid transporter, palmitoyl-DL-carnitine, were also found to promote the nasal absorption of hGH in this model, with relative bioavailabilities of 12.2 and 22.1%, respectively.",Nasal absorption enhancers for biosynthetic human growth hormone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395807/),%,12.2,144699,DB06151,Acetylcysteine
,2395807,relative bioavailabilities,"A mucolytic agent, N-acetyl-L-cysteine, and a transmembrane fatty acid transporter, palmitoyl-DL-carnitine, were also found to promote the nasal absorption of hGH in this model, with relative bioavailabilities of 12.2 and 22.1%, respectively.",Nasal absorption enhancers for biosynthetic human growth hormone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395807/),%,22.1,144700,DB06151,Acetylcysteine
,20053818,elimination half-life,"After a single 80-mg (100 microCi) oral dose of [1'-(14)C]stavudine, approximately 95% of the radioactive dose was excreted in urine with an elimination half-life of 2.35 h.",Disposition of [1'-(14)C]stavudine after oral administration to humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20053818/),h,2.35,145888,DB06151,Acetylcysteine
,6850648,initial half-life,The disappearance kinetics of Adriamycin could adequately be described by a biexponential equation with an initial half-life of 8-min and a terminal half-life of 30 hr.,Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6850648/),min,8,147369,DB06151,Acetylcysteine
,6850648,terminal half-life,The disappearance kinetics of Adriamycin could adequately be described by a biexponential equation with an initial half-life of 8-min and a terminal half-life of 30 hr.,Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6850648/),h,30,147370,DB06151,Acetylcysteine
,1468429,peak level,The substance was well absorbed with a mean peak level of 19.21 +/- 3.94 mg/l in the fasting state; it was primarily excreted in active form via the kidneys (urine recovery/24 h: 86-92%).,Pharmacokinetics of loracarbef and interaction with acetylcysteine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1468429/),[mg] / [l],19.21,153063,DB06151,Acetylcysteine
,1468429,urine recovery/24 h,The substance was well absorbed with a mean peak level of 19.21 +/- 3.94 mg/l in the fasting state; it was primarily excreted in active form via the kidneys (urine recovery/24 h: 86-92%).,Pharmacokinetics of loracarbef and interaction with acetylcysteine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1468429/),%,86-92,153064,DB06151,Acetylcysteine
,1468429,elimination half-life,The elimination half-life ranged from 70.3 to 102.0 min.,Pharmacokinetics of loracarbef and interaction with acetylcysteine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1468429/),min,70.3 to 102.0,153065,DB06151,Acetylcysteine
,23363356,elimination half-life,"Mean ± SD elimination half-life was 0.78 ± 0.16 hours and 1.34 ± 0.24 hours for the IV and oral routes of administration, respectively.",Pharmacokinetics of N-acetylcysteine after oral and intravenous administration to healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363356/),h,0.78,157939,DB06151,Acetylcysteine
,23363356,elimination half-life,"Mean ± SD elimination half-life was 0.78 ± 0.16 hours and 1.34 ± 0.24 hours for the IV and oral routes of administration, respectively.",Pharmacokinetics of N-acetylcysteine after oral and intravenous administration to healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363356/),h,1.34,157940,DB06151,Acetylcysteine
,23363356,bioavailability,Mean bioavailability of NAC after oral administration was 19.3 ± 4.4%.,Pharmacokinetics of N-acetylcysteine after oral and intravenous administration to healthy cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363356/),%,19.3,157941,DB06151,Acetylcysteine
,21374646,mass transition pairs,"The mass transition pairs of N-acetylcysteine and the isotope-labeled internal standard d3-N-acetylcysteine were 164 → 122 and 167 → 123, respectively.",Liquid chromatography tandem mass spectrometry method for determination of N-acetylcysteine in human plasma using an isotope-labeled internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21374646/),,164,160446,DB06151,Acetylcysteine
,21374646,mass transition pairs,"The mass transition pairs of N-acetylcysteine and the isotope-labeled internal standard d3-N-acetylcysteine were 164 → 122 and 167 → 123, respectively.",Liquid chromatography tandem mass spectrometry method for determination of N-acetylcysteine in human plasma using an isotope-labeled internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21374646/),,122,160447,DB06151,Acetylcysteine
,21374646,mass transition pairs,"The mass transition pairs of N-acetylcysteine and the isotope-labeled internal standard d3-N-acetylcysteine were 164 → 122 and 167 → 123, respectively.",Liquid chromatography tandem mass spectrometry method for determination of N-acetylcysteine in human plasma using an isotope-labeled internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21374646/),,167,160448,DB06151,Acetylcysteine
,2775620,t1/2,"2. A pronounced stereoselectivity was observed: the mercapturate formed from R-BIU was excreted with a t1/2 of 1.5 +/- 0.4 h, while that from S-BIU showed a t1/2 of 3.1 +/- 1.3 h.",Stereoselectivity in the urinary excretion of the mercapturates of (R-) and (S-) alpha-bromoisovalerylurea in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775620/),h,1.5,174575,DB06151,Acetylcysteine
,2775620,t1/2,"2. A pronounced stereoselectivity was observed: the mercapturate formed from R-BIU was excreted with a t1/2 of 1.5 +/- 0.4 h, while that from S-BIU showed a t1/2 of 3.1 +/- 1.3 h.",Stereoselectivity in the urinary excretion of the mercapturates of (R-) and (S-) alpha-bromoisovalerylurea in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775620/),h,3.1,174576,DB06151,Acetylcysteine
,2582712,Ki,"Studies in microsomes prepared from two human organ donors indicated that cimetidine inhibited acetaminophen reactive metabolite formation noncompetitively, with Ki values of 0.35 mmol/L and 0.32 mmol/L for the respective livers, which is 5 to 10 times the putative cimetidine concentration required for therapeutic effect.",Lack of effect of cimetidine on acetaminophen disposition in humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2582712/),[mM] / [l],0.35,184247,DB06151,Acetylcysteine
,2582712,Ki,"Studies in microsomes prepared from two human organ donors indicated that cimetidine inhibited acetaminophen reactive metabolite formation noncompetitively, with Ki values of 0.35 mmol/L and 0.32 mmol/L for the respective livers, which is 5 to 10 times the putative cimetidine concentration required for therapeutic effect.",Lack of effect of cimetidine on acetaminophen disposition in humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2582712/),[mM] / [l],0.32,184248,DB06151,Acetylcysteine
,24038334,flow rate,"Deproteinized rat plasma containing racemic sitagliptin was derivatized with o-phthalaldehyde and N-acetyl-L-cysteine under alkaline conditions, converted to diastereomers, and separated on a Lichrospher 100 RP-18e column using 20 mM phosphate buffer and methanol (45:55 v/v) as a mobile phase under isocratic mode of elution at a flow rate of 1.0 mL/min.",Precolumn o-phthalaldehyde-N-acetyl-L-cysteine derivatization followed by RP-HPLC separation and fluorescence detection of sitagliptin enantiomers in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24038334/),[ml] / [min],1.0,184338,DB06151,Acetylcysteine
,8308946,%ME,"The prediction of concentrations between 2 to 4 h and 4 to 4.5 h after ingestion with only population-based parameter estimates resulted in %ME of 17.0 and 13.2, respectively, and %MAE of 36.5 and 35.1, respectively.",Prediction of acetaminophen concentrations in overdose patients using a Bayesian pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8308946/),,17.0,198278,DB06151,Acetylcysteine
,8308946,%ME,"The prediction of concentrations between 2 to 4 h and 4 to 4.5 h after ingestion with only population-based parameter estimates resulted in %ME of 17.0 and 13.2, respectively, and %MAE of 36.5 and 35.1, respectively.",Prediction of acetaminophen concentrations in overdose patients using a Bayesian pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8308946/),,13.2,198279,DB06151,Acetylcysteine
,8308946,%MAE,"The prediction of concentrations between 2 to 4 h and 4 to 4.5 h after ingestion with only population-based parameter estimates resulted in %ME of 17.0 and 13.2, respectively, and %MAE of 36.5 and 35.1, respectively.",Prediction of acetaminophen concentrations in overdose patients using a Bayesian pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8308946/),,36.5,198280,DB06151,Acetylcysteine
,8308946,%MAE,"The prediction of concentrations between 2 to 4 h and 4 to 4.5 h after ingestion with only population-based parameter estimates resulted in %ME of 17.0 and 13.2, respectively, and %MAE of 36.5 and 35.1, respectively.",Prediction of acetaminophen concentrations in overdose patients using a Bayesian pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8308946/),,35.1,198281,DB06151,Acetylcysteine
,25064164,terminal elimination half-life,"Maternal clearance (CL) of NAC was faster than in nonpregnant adults, with a terminal elimination half-life of 1.2 ± 0.2 hours.",Antenatal pharmacokinetics and placental transfer of N-acetylcysteine in chorioamnionitis for fetal neuroprotection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064164/),h,1.2,205700,DB06151,Acetylcysteine
,25064164,cord to maternal ratio,"The NAC cord to maternal ratio was 1.4 ± 0.8, suggesting rapid placental transfer and slower rate of fetal CL.",Antenatal pharmacokinetics and placental transfer of N-acetylcysteine in chorioamnionitis for fetal neuroprotection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064164/),,1.4,205701,DB06151,Acetylcysteine
,25064164,terminal elimination half-life,"Neonatal PK estimates for near-term compared with preterm infants showed a significantly shorter terminal elimination half-life (5.1 vs 7.5 hours, respectively) and greater CL (53.7 vs 45.0 mL/h/kg, respectively).",Antenatal pharmacokinetics and placental transfer of N-acetylcysteine in chorioamnionitis for fetal neuroprotection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064164/),h,5.1,205702,DB06151,Acetylcysteine
,25064164,terminal elimination half-life,"Neonatal PK estimates for near-term compared with preterm infants showed a significantly shorter terminal elimination half-life (5.1 vs 7.5 hours, respectively) and greater CL (53.7 vs 45.0 mL/h/kg, respectively).",Antenatal pharmacokinetics and placental transfer of N-acetylcysteine in chorioamnionitis for fetal neuroprotection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064164/),h,7.5,205703,DB06151,Acetylcysteine
,25064164,CL,"Neonatal PK estimates for near-term compared with preterm infants showed a significantly shorter terminal elimination half-life (5.1 vs 7.5 hours, respectively) and greater CL (53.7 vs 45.0 mL/h/kg, respectively).",Antenatal pharmacokinetics and placental transfer of N-acetylcysteine in chorioamnionitis for fetal neuroprotection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064164/),[ml] / [h·kg],53.7,205704,DB06151,Acetylcysteine
,25064164,CL,"Neonatal PK estimates for near-term compared with preterm infants showed a significantly shorter terminal elimination half-life (5.1 vs 7.5 hours, respectively) and greater CL (53.7 vs 45.0 mL/h/kg, respectively).",Antenatal pharmacokinetics and placental transfer of N-acetylcysteine in chorioamnionitis for fetal neuroprotection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064164/),[ml] / [h·kg],45.0,205705,DB06151,Acetylcysteine
,28826881,zeta potential,"Thanks to the good physical characteristics (mean diameter <100 nm, zeta potential about -8 mV) NPs can reach skeletal tissue in particular femoral head and proximal tibia epiphysis at the sixth hour after injection, remaining in the tissues till 24 h.",Polyethylene Glycol-Poly-Lactide-co-Glycolide Block Copolymer-Based Nanoparticles as a Potential Tool for Off-Label Use of N-Acetylcysteine in the Treatment of Diastrophic Dysplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28826881/),m,-,207298,DB06151,Acetylcysteine
,28826881,zeta potential,"Thanks to the good physical characteristics (mean diameter <100 nm, zeta potential about -8 mV) NPs can reach skeletal tissue in particular femoral head and proximal tibia epiphysis at the sixth hour after injection, remaining in the tissues till 24 h.",Polyethylene Glycol-Poly-Lactide-co-Glycolide Block Copolymer-Based Nanoparticles as a Potential Tool for Off-Label Use of N-Acetylcysteine in the Treatment of Diastrophic Dysplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28826881/),m,8,207299,DB06151,Acetylcysteine
,28826881,peak concentration,"Furthermore, pharmacokinetic study revealed a sustained N-Ac concentration in plasma with a peak concentration of 2.48 ± 1.72 μM at the 24th hour after injection.",Polyethylene Glycol-Poly-Lactide-co-Glycolide Block Copolymer-Based Nanoparticles as a Potential Tool for Off-Label Use of N-Acetylcysteine in the Treatment of Diastrophic Dysplasia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28826881/),μM,2.48,207300,DB06151,Acetylcysteine
,11401302,recovery,The recovery of PEITC assessed on multiple days was 96.6 +/- 1.5% and was 100% for PEITC--GSH and PEITC--NAC.,High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401302/),%,96.6,211431,DB06151,Acetylcysteine
,11401302,recovery,The recovery of PEITC assessed on multiple days was 96.6 +/- 1.5% and was 100% for PEITC--GSH and PEITC--NAC.,High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401302/),%,100,211432,DB06151,Acetylcysteine
,11401302,plasma ITC,"In clinical studies, mean plasma ITC level of 413 +/- 193 nM PEITC equivalents was determined for a non-dietary-controlled group of 23 subjects.",High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401302/),nM,413,211433,DB06151,Acetylcysteine
,27788591,peak concentration,"Chloroform was measured using headspace gas chromatograph mass spectrometry, with a peak concentration of 2.00 μg/mL, 4 h 20 min post-ingestion.","Chloroform ingestion causing severe gastrointestinal injury, hepatotoxicity and dermatitis confirmed with plasma chloroform concentrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27788591/),[μg] / [ml],2.00,212444,DB06151,Acetylcysteine
,27788591,elimination half-life,The concentration-time data fitted a 1-compartment model with elimination half-life 6.5 h.,"Chloroform ingestion causing severe gastrointestinal injury, hepatotoxicity and dermatitis confirmed with plasma chloroform concentrations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27788591/),h,6.5,212445,DB06151,Acetylcysteine
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,17144,214135,DB06151,Acetylcysteine
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,75,214136,DB06151,Acetylcysteine
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,128,214137,DB06151,Acetylcysteine
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,18.4,214138,DB06151,Acetylcysteine
,26484583,clearance,"There was a significant alteration in the pharmacokinetics of acetylcysteine during hemodialysis; the area under the curve (AUC) decreased 41%, the mean extraction ratio was 51%, the mean hemodialytic clearance was 114.01 ml/kg/h, and a mean 166.75 mg/h was recovered in the effluent or 41% of the hourly dose.",The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26484583/),[ml] / [h·kg],114.01,219207,DB06151,Acetylcysteine
,26484583,clearance,"Alteration in the pharmacokinetics of acetylcysteine during continuous venovenous hemofiltration did not appear to be significant: the AUC decreased 13%, the mean clearance was 31.77 ml/kg/h and a mean 62.12 mg/h was recovered in the effluent or 14% of the hourly dose.",The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26484583/),[ml] / [h·kg],31.77,219208,DB06151,Acetylcysteine
,26484583,clearance,"Alteration in the pharmacokinetics of acetylcysteine during continuous venovenous hemofiltration did not appear to be significant: the AUC decreased 13%, the mean clearance was 31.77 ml/kg/h and a mean 62.12 mg/h was recovered in the effluent or 14% of the hourly dose.",The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26484583/),[mg] / [h],62.12,219209,DB06151,Acetylcysteine
,1484108,maximum concentrations,"Average maximum concentrations were 57.5 and 6.3 ng/ml for S- and R-tranylcypromine, respectively.",Enantiospecific high-performance liquid chromatographic assay with fluorescence detection for the monoamine oxidase inhibitor tranylcypromine and its applicability in pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484108/),[ng] / [ml],57.5,221654,DB06151,Acetylcysteine
,1484108,maximum concentrations,"Average maximum concentrations were 57.5 and 6.3 ng/ml for S- and R-tranylcypromine, respectively.",Enantiospecific high-performance liquid chromatographic assay with fluorescence detection for the monoamine oxidase inhibitor tranylcypromine and its applicability in pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484108/),[ng] / [ml],6.3,221655,DB06151,Acetylcysteine
,25505606,systemic clearance rate,Intravenous administration of MM-433593 to cynomolgus monkeys produced a rapid distribution phase and slower elimination phase with a mean systemic clearance rate of 8-11 mL/min/kg.,"Metabolism and disposition of MM-433593, a selective FAAH-1 inhibitor, in monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25505606/),[ml] / [kg·min],8-11,226352,DB06151,Acetylcysteine
,25505606,Absolute oral bioavailability,Absolute oral bioavailability was determined to be 14-21% with maximum plasma concentrations reached ∼3 h (T max) following a 10 mg/kg oral dose.,"Metabolism and disposition of MM-433593, a selective FAAH-1 inhibitor, in monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25505606/),%,14-21,226353,DB06151,Acetylcysteine
,25505606,terminal half-life,"The average terminal half-life of MM-433593 was 17-20 h, and there were no qualitative sex differences in the metabolite profile of MM-433593.","Metabolism and disposition of MM-433593, a selective FAAH-1 inhibitor, in monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25505606/),h,17-20,226354,DB06151,Acetylcysteine
,11420329,absorption half life (t(abs)),"After modelling of the data, the following pharmacokinetic variables were calculated: absorption half life (t(abs)), 0.51 hours; volume of distribution (V/F(oral)), 0.80 litres/kg; clearance (CL/F(oral)), 0.22 litres/h; they were consistent with population pharmacokinetic studies.",Paracetamol overdose in a preterm neonate. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420329/),h,0.51,231594,DB06151,Acetylcysteine
,11420329,volume of distribution (V/F(oral)),"After modelling of the data, the following pharmacokinetic variables were calculated: absorption half life (t(abs)), 0.51 hours; volume of distribution (V/F(oral)), 0.80 litres/kg; clearance (CL/F(oral)), 0.22 litres/h; they were consistent with population pharmacokinetic studies.",Paracetamol overdose in a preterm neonate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420329/),[l] / [kg],0.80,231595,DB06151,Acetylcysteine
,11420329,clearance (CL/F(oral)),"After modelling of the data, the following pharmacokinetic variables were calculated: absorption half life (t(abs)), 0.51 hours; volume of distribution (V/F(oral)), 0.80 litres/kg; clearance (CL/F(oral)), 0.22 litres/h; they were consistent with population pharmacokinetic studies.",Paracetamol overdose in a preterm neonate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420329/),[l] / [h],0.22,231596,DB06151,Acetylcysteine
,11420329,plasma half life (Tbeta),"The increased plasma half life (Tbeta) of 5.69 hours thus reflected normal slower metabolism in infants, rather than toxicity.",Paracetamol overdose in a preterm neonate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420329/),h,5.69,231597,DB06151,Acetylcysteine
,8448420,half-life,The half-life of SCOTP in blood was 8.0 +/- 1.1 min.,Toxicokinetics of [14C]-saligenin cyclic-o-tolyl phosphate in anesthetized male F-344 rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8448420/),min,8.0,232485,DB06151,Acetylcysteine
,27111731,tmax,The pharmacokinetics of 6 following a single oral dose indicated that the prodrug was rapidly absorbed and converted to 1 with a tmax of 15 min.,"Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27111731/),min,15,232851,DB06151,Acetylcysteine
,21263015,systemic exposure,"The mean systemic exposure in the rat model was 18.72 mM·h (range, 9.92-30.02 mM·h), compared to the mean systemic exposure found in treated children (14.48 mM·h; range, 6.22-32.96 mM·h).",N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: translational pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21263015/),h·mM,18.72,242019,DB06151,Acetylcysteine
,21263015,systemic exposure,"The mean systemic exposure in the rat model was 18.72 mM·h (range, 9.92-30.02 mM·h), compared to the mean systemic exposure found in treated children (14.48 mM·h; range, 6.22-32.96 mM·h).",N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: translational pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21263015/),h·mM,14.48,242020,DB06151,Acetylcysteine
,3140711,T1/2 beta,"Pharmacokinetic studies of MMC in normal mice, demonstrated rapid plasma elimination (T1/2 beta = 0.53 hrs) and substantial drug distribution to the bone marrow which was enhanced by NAC.",Mitomycin C toxicity and pharmacokinetics in mice given sulfur nucleophiles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140711/),h,0.53,247082,DB06151,Acetylcysteine
,24889523,maximum plasma concentrations,"Following i.v. administration, the maximum plasma concentrations of Cos and Dehy were observed to be 12.29 ± 1.47 and 5.79 ± 0.13 µg/mL, respectively.",Study on the pharmacokinetics and metabolism of costunolide and dehydrocostus lactone in rats by HPLC-UV and UPLC-Q-TOF/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24889523/),[μg] / [ml],12.29,249569,DB06151,Acetylcysteine
,24889523,maximum plasma concentrations,"Following i.v. administration, the maximum plasma concentrations of Cos and Dehy were observed to be 12.29 ± 1.47 and 5.79 ± 0.13 µg/mL, respectively.",Study on the pharmacokinetics and metabolism of costunolide and dehydrocostus lactone in rats by HPLC-UV and UPLC-Q-TOF/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24889523/),[μg] / [ml],5.79,249570,DB06151,Acetylcysteine
,2598977,oral bioavailability,The oral bioavailability of the NAC tablets was 103%.,Bioavailability of suckable tablets of oral N-acetylcysteine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598977/),%,103,250262,DB06151,Acetylcysteine
,24134534,total clearance,"A single run of 3-4 h of haemodialysis removed 10-20 g of acetaminophen (48-80% of remaining body burden), reduced serum acetaminophen concentrations by 56-84% (total clearance 3.4-7.8 mL/kg/min), accelerated native acetaminophen clearance (mean elimination half-life 580 min pre-dialysis, 120 min during and 340 min post-dialysis) and corrected acidemia.",Antidote removal during haemodialysis for massive acetaminophen overdose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134534/),[ml] / [kg·min],3.4-7.8,250716,DB06151,Acetylcysteine
,24134534,elimination half-life,"A single run of 3-4 h of haemodialysis removed 10-20 g of acetaminophen (48-80% of remaining body burden), reduced serum acetaminophen concentrations by 56-84% (total clearance 3.4-7.8 mL/kg/min), accelerated native acetaminophen clearance (mean elimination half-life 580 min pre-dialysis, 120 min during and 340 min post-dialysis) and corrected acidemia.",Antidote removal during haemodialysis for massive acetaminophen overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134534/),min,580,250717,DB06151,Acetylcysteine
,24134534,elimination half-life,"A single run of 3-4 h of haemodialysis removed 10-20 g of acetaminophen (48-80% of remaining body burden), reduced serum acetaminophen concentrations by 56-84% (total clearance 3.4-7.8 mL/kg/min), accelerated native acetaminophen clearance (mean elimination half-life 580 min pre-dialysis, 120 min during and 340 min post-dialysis) and corrected acidemia.",Antidote removal during haemodialysis for massive acetaminophen overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134534/),min,120,250718,DB06151,Acetylcysteine
,24134534,elimination half-life,"A single run of 3-4 h of haemodialysis removed 10-20 g of acetaminophen (48-80% of remaining body burden), reduced serum acetaminophen concentrations by 56-84% (total clearance 3.4-7.8 mL/kg/min), accelerated native acetaminophen clearance (mean elimination half-life 580 min pre-dialysis, 120 min during and 340 min post-dialysis) and corrected acidemia.",Antidote removal during haemodialysis for massive acetaminophen overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134534/),min,340,250719,DB06151,Acetylcysteine
,24134534,Extraction ratios,Extraction ratios of acetylcysteine across the dialysis circuit ranged from 73% to 87% (dialysance 3.0 to 5.3 mL/kg/min).,Antidote removal during haemodialysis for massive acetaminophen overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134534/),%,73,250720,DB06151,Acetylcysteine
,24134534,Extraction ratios,Extraction ratios of acetylcysteine across the dialysis circuit ranged from 73% to 87% (dialysance 3.0 to 5.3 mL/kg/min).,Antidote removal during haemodialysis for massive acetaminophen overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134534/),%,87,250721,DB06151,Acetylcysteine
,6512918,plasma half-life (t1/2,"Relative to Group II, treatment with NAC (Group I) enhanced the elimination of AP from the body as indicated by the decreased plasma half-life (t1/2 = 1.06 h for Group I v. 1.78 h for Group II) and a higher elimination rate constant (beta = 0.67/h for Group I v. 0.40/h for Group II).",Effect of antidotal N-acetylcysteine on the pharmacokinetics of acetaminophen in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512918/),h,1.06,256688,DB06151,Acetylcysteine
,6512918,plasma half-life (t1/2,"Relative to Group II, treatment with NAC (Group I) enhanced the elimination of AP from the body as indicated by the decreased plasma half-life (t1/2 = 1.06 h for Group I v. 1.78 h for Group II) and a higher elimination rate constant (beta = 0.67/h for Group I v. 0.40/h for Group II).",Effect of antidotal N-acetylcysteine on the pharmacokinetics of acetaminophen in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512918/),h,1.78,256689,DB06151,Acetylcysteine
,6512918,elimination rate constant (beta,"Relative to Group II, treatment with NAC (Group I) enhanced the elimination of AP from the body as indicated by the decreased plasma half-life (t1/2 = 1.06 h for Group I v. 1.78 h for Group II) and a higher elimination rate constant (beta = 0.67/h for Group I v. 0.40/h for Group II).",Effect of antidotal N-acetylcysteine on the pharmacokinetics of acetaminophen in dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512918/),1/[h],0.67,256690,DB06151,Acetylcysteine
,6512918,elimination rate constant (beta,"Relative to Group II, treatment with NAC (Group I) enhanced the elimination of AP from the body as indicated by the decreased plasma half-life (t1/2 = 1.06 h for Group I v. 1.78 h for Group II) and a higher elimination rate constant (beta = 0.67/h for Group I v. 0.40/h for Group II).",Effect of antidotal N-acetylcysteine on the pharmacokinetics of acetaminophen in dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512918/),1/[h],0.40,256691,DB06151,Acetylcysteine
,6512918,area under plasma concentration curve,Changes in the area under plasma concentration curve data (AUC = 0.39 mg.h/ml for Group I v. 0.65 mg.h/ml for Group II) were associated with a 61% increase in total body clearance of AP in Group I.,Effect of antidotal N-acetylcysteine on the pharmacokinetics of acetaminophen in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512918/),[h·mg] / [ml],0.39,256692,DB06151,Acetylcysteine
,6512918,area under plasma concentration curve,Changes in the area under plasma concentration curve data (AUC = 0.39 mg.h/ml for Group I v. 0.65 mg.h/ml for Group II) were associated with a 61% increase in total body clearance of AP in Group I.,Effect of antidotal N-acetylcysteine on the pharmacokinetics of acetaminophen in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512918/),[h·mg] / [ml],0.65,256693,DB06151,Acetylcysteine
,22134116,vesi,"Mean vesicle size was 45-65 nm for liposome preparations downsized by homogenization, and 80-100 nm when downsized by extrusion, the latter displaying narrower polydispersity.",Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),nm,45-65,269030,DB06151,Acetylcysteine
,22134116,vesi,"Mean vesicle size was 45-65 nm for liposome preparations downsized by homogenization, and 80-100 nm when downsized by extrusion, the latter displaying narrower polydispersity.",Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),,80-100,269031,DB06151,Acetylcysteine
,22134116,to,MLP to phospholipid mole ratio was 5% (~20 μg MMC-equivalents/μmol).,Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),%,5,269032,DB06151,Acetylcysteine
,22134116,mole ratio,MLP to phospholipid mole ratio was 5% (~20 μg MMC-equivalents/μmol).,Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),%,5,269033,DB06151,Acetylcysteine
,22134116,mole ratio,MLP to phospholipid mole ratio was 5% (~20 μg MMC-equivalents/μmol).,Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),μg,20,269034,DB06151,Acetylcysteine
,14555815,effective concentrations,"Further pharmacokinetic study into the systemic administration of these antioxidants is necessary, using effective concentrations of 5-40 mM for both N-acetyl-L-cysteine and glutathione, and 1-50 units of catalase.",Effects of N-acetyl-L-cysteine and glutathione on antioxidant status of human serum and 3T3 fibroblasts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555815/),m,5-40,273151,DB06151,Acetylcysteine
